NewsRoom Articles - BioMedWire (BMW)

FridayApr 24, 2026 11:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) AI Platform Brings Precision to Heart Health

At the core of Cardio Diagnostics’ approach is the use of artificial intelligence to integrate multi-omic data to provide a more comprehensive view of cardiovascular health. The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk. CDIO’s focus on accessibility and scalability is also notable. Cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. Cardio Diagnostics Holdings (NASDAQ: CDIO) is at the forefront of this shift, developing a proprietary…

FridayApr 24, 2026 10:00 am

Survey Finds That American Adults Want Health Inequities Eliminated

Last fall, Johns Hopkins School of Nursing through its Institute for Policy Solutions conducted a survey on health inequities and the full report from that survey was released weeks ago. The findings of that poll offer valuable insights that policymakers and all stakeholders need to weigh while making decisions impacting the health of Americans. The majority (70%) of the respondents say health care is a right and that it shouldn’t be treated as a privilege. The survey found that while there is a sense that Americans are heavily polarized on national issues, this isn’t the case when it comes to matters of health care. Notably, 62% of those who participated in the survey revealed…

ThursdayApr 23, 2026 10:00 am

New Urine Test Could Predict Response to Bladder Cancer Treatment

Researchers have developed a urine test that can screen for tumor DNA and detect whether a patient has residual bladder cancer after they have undergone surgery to remove the tumor. This test may also detect whether immunotherapy treatment administered after surgery has been effective or residual bladder cancer remains. The study containing those findings appeared in the journal Cell. If this urine test is successfully validated in larger clinical trials, it could mark a major shift in the way bladder cancer is treated. Conventionally, bladder cancer is monitored by obtaining a tissue sample for molecular analysis. This approach is costly and subjects patients to several invasive procedures. With this new test, all a…

WednesdayApr 22, 2026 9:00 am

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is supported by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to incorporate clinical progress, probability of success and expected commercialization timelines into measurable balance sheet value. Companies at the…

TuesdayApr 21, 2026 10:00 am

Why Molecular Testing is Increasingly Important in CNS Cancers

Primary and metastatic central nervous system (CNS) tumors can have extraordinary biological and anatomical complexity, and these tumors can be hard to identify using traditional imaging or histopathology analysis. Molecular analysis has emerged as a major way to identify these tumors and help medical teams plan how best to help those diagnosed with these cancers. Biomarker testing is a growing field that is making it possible for the molecular structure of CNS cancers to be analyzed for not only diagnostic purposes but also other functions as well. Recent advances like the detection of tumor RNA particles in blood samples now mean that a brain cancer can be identified and tracked without subjecting patients to…

MondayApr 20, 2026 10:30 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Broadens AI Intoxication Detection Platform with Launch of Intox Collect(TM)

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The Intox Collect(TM) technology enhances the company’s ability to collect and analyze voice and facial recognition data tied to drug and alcohol impairment. MindBio says the platform broadens detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants. The company’s AI model currently uses more than 50 million data points, with management expecting that figure to increase further. MindBio is developing Edge AI kiosk hardware for enterprise deployment, with prototype testing expected in the second quarter of 2026. Target industries include mining, aviation,…

MondayApr 20, 2026 9:00 am

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), are keenly aware of this evolution and…

FridayApr 17, 2026 12:10 pm

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease. SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug…

FridayApr 17, 2026 10:50 am

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug…

FridayApr 17, 2026 10:00 am

Americans are Supplementing Healthcare Visits with AI, Gallup Survey Finds

A survey that was conducted toward the end of last year by Gallup and West Health found that a sizeable number of Americans are using AI to supplement their interactions with healthcare providers. However, the specifics of how people used these digital tools varied based on age groups, income level and motivations. The survey was carried out from October 27 to December 22 in 2025. A total of 5,500 adults participated in the poll that was designed to be nationally representative. Among those who had used AI in the last 30 days, 59% said they used AI tools to conduct research on their own prior to visiting their doctor.…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) AI Platform Brings Precision to Heart Health

Survey Finds That American Adults Want Health Inequities Eliminated

New Urine Test Could Predict Response to Bladder Cancer Treatment

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

Why Molecular Testing is Increasingly Important in CNS Cancers

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Broadens AI Intoxication Detection Platform with Launch of Intox Collect(TM)

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Americans are Supplementing Healthcare Visits with AI, Gallup Survey Finds

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search